Gregory J. Hayes Joins BD's Board of Directors
BD (Becton, Dickinson and Company) (NYSE: BDX), a world leader in medical technology, has recently welcomed Gregory J. Hayes to its board of directors. This strategic appointment marks an important step for BD as it continues to enhance its governance structure and commit to top-tier leadership. Hayes will bring his extensive background in executive leadership to the forefront at a time when BD is poised for significant growth.
About Gregory J. Hayes
At 64, Hayes serves as the executive chairman of the board for RTX Corporation, recognized globally as a leader in aerospace and defense. His impressive career spans three decades, during which he has held various top positions—demonstrating skillful leadership in corporate financial strategy, business development, and transformative corporate projects, including mergers and acquisitions.
Experience and Expertise
Before his role at RTX, Hayes dedicated over 20 years to United Technologies Corporation (UTC), where he rose to the position of CEO in 2014. His management of UTC has laid the groundwork for what is now RTX, following a pivotal merger that amalgamated multiple aerospace divisions. Notably, he served as UTC's CFO from 2008 to 2014, emphasizing his background in financial management.
Strategic Significance for BD
Tom Polen, chairman and CEO of BD, expressed confidence in Hayes's addition to the team, especially as the company enters a transformative phase focused on enhancing shareholder value. Hayes’s experience aligns well with BD's ongoing initiatives to separate its Diagnostic Solutions and Biosciences businesses and establish a focused medtech leader committed to innovation and efficiency.
Hayes on BD's Future
In his own words, Hayes described BD as having a remarkable legacy as a medical device manufacturer central to health care infrastructure. He is excited about the opportunities ahead and is committed to utilizing his knowledge for the successful evolution of 'New BD.' His vision emphasizes driving growth and expanding capabilities to deliver long-term value to all stakeholders.
About BD
BD stands as a prominent global medical technology entity. Its mission revolves around improving health through advanced medical discovery, diagnostic excellence, and effective care delivery solutions. With a workforce of over 70,000 employees, BD is dedicated to supporting healthcare heroes by innovating critical technologies that enhance patient and clinician experiences. The company collaborates worldwide to tackle pressing health challenges, focusing on elevating care standards and expanding accessibility.
Frequently Asked Questions
Who is Gregory J. Hayes?
Gregory J. Hayes is the newly appointed board member of BD, with a strong background in executive leadership and corporate strategy.
What is BD?
BD (Becton, Dickinson and Company) is a leading global medical technology company focused on improving healthcare outcomes through innovative solutions.
What is the significance of Hayes's appointment?
Hayes's appointment aligns with BD's commitment to governance and innovation, enhancing the board's expertise during a transformative period for the company.
What prior roles has Hayes held?
Before joining BD, Hayes was executive chairman at RTX Corporation and held executive roles for two decades at United Technologies Corporation.
How does Hayes's experience benefit BD?
Hayes's extensive experience in corporate finance and strategic leadership is expected to be instrumental in guiding BD through its operational enhancement initiatives.
